Cnbx Pharmaceuticals Inc. (CNBX) — SEC Filings
Cnbx Pharmaceuticals Inc. (CNBX) — 12 SEC filings. Latest: 10-K (Dec 1, 2025). Includes 6 10-Q, 2 10-K, 2 8-K.
View Cnbx Pharmaceuticals Inc. on SEC EDGAR
Overview
Cnbx Pharmaceuticals Inc. (CNBX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Dec 1, 2025: CNBX Pharmaceuticals Inc., a clinical-stage company, reported no meaningful revenue from oil and gas exploration, leading to a business model transition in 2014 to focus on cannabinoid-based cancer treatments. The company's lead product candidates are Cannabics SR for Cancer Anorexia Cachexia Syndro
Sentiment Summary
Across 12 filings, the sentiment breakdown is: 2 bearish, 10 neutral. The dominant filing sentiment for Cnbx Pharmaceuticals Inc. is neutral.
Filing Type Overview
Cnbx Pharmaceuticals Inc. (CNBX) has filed 2 10-K, 6 10-Q, 2 8-K, 2 SC 13G/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (12)
| Date | Form | Description | Risk |
|---|---|---|---|
| Dec 1, 2025 | 10-K | CNBX Pivots to Cannabinoid Cancer Drugs, Eyes 2026 Clinical Trials | high |
| Jul 14, 2025 | 10-Q | CNBX Pharmaceuticals Reports No Revenue, Minimal Net Loss in Q3 | high |
| Apr 14, 2025 | 10-Q | CNBX Pharmaceuticals Inc. Files Q2 2025 10-Q | low |
| Jan 30, 2025 | 8-K | CNBX Pharmaceuticals Inc. Files 8-K for Material Agreement | medium |
| Jan 13, 2025 | 10-Q | CNBX Pharmaceuticals Files Q1 2025 10-Q | medium |
| Nov 29, 2024 | 10-K | CNBX Pharmaceuticals Files 2024 10-K | medium |
| Nov 14, 2024 | SC 13G/A | SC 13G/A Filing | |
| Jul 15, 2024 | 10-Q | CNBX Pharmaceuticals Files 10-Q for Period Ending May 31, 2024 | medium |
| Apr 16, 2024 | 10-Q | CNBX Pharmaceuticals Inc. Files 10-Q for Period Ending February 29, 2024 | low |
| Mar 22, 2024 | 8-K | CNBX Pharmaceuticals Changes Auditors | low |
| Feb 13, 2024 | SC 13G/A | SC 13G/A Filing | |
| Jan 12, 2024 | 10-Q | CNBX Pharmaceuticals Inc. Files 10-Q for Period Ending November 30, 2023 | low |
Risk Profile
Risk Assessment: Of CNBX's 10 recent filings, 2 were flagged as high-risk, 4 as medium-risk, and 4 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | Not Disclosed |
| EPS | Not Disclosed |
| Debt-to-Equity | Not Disclosed |
| Cash Position | Not Disclosed |
| Operating Margin | Not Disclosed |
| Total Assets | Not Disclosed |
| Total Debt | Not Disclosed |
Key Executives
- Dr. Erez Scapa
- Dr. Dana Ben-Ami Shor
- Dr. Gil Bar-Sela
Industry Context
CNBX operates in the highly competitive and rapidly evolving oncology drug development sector. The company is focusing on cannabinoid-based therapies, a niche area with growing scientific interest but significant regulatory uncertainty. Key trends include the search for novel mechanisms of action to overcome treatment resistance and improve patient quality of life, particularly for symptom management like CACS. The industry is characterized by long development cycles, high R&D costs, and the need for substantial capital investment.
Top Tags
10-Q (5) · Pharmaceuticals (4) · pharmaceuticals (4) · Speculative Investment (2) · CNBX (2) · SEC Filing (2) · Biotechnology (1) · Cannabinoids (1) · Cancer Treatment (1) · Clinical Trials (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Aggregate market value of Common Stock held by non-affiliates | $251,840 | as of February 28, 2025, based on $0.0076 closing price |
| Shares of Common Stock outstanding | 553,962,206 | as of November 20, 2025 |
| Year of business model transition | 2014 | from mining to biotech |
| Target year for Phase I/II clinical trials | 2026 | for Cannabics SR and RCC-33, contingent on fundraising |
| Reverse stock split ratio | 1:120 | effected on May 12, 2022 |
| Prevalence of CACS | 40-80% | estimated range from cancer diagnosis to advanced stages |
| Shares issued to Cannabics Inc. | 18,239,594 | to acquire institutional knowledge and R&D technology |
| Working funds tendered by Cannabics Inc. | $150,000 | earmarked for prospective projects |
| Revenue | $0 | for three and nine months ended May 31, 2025, indicating pre-revenue status |
| Net Loss | $1,000 | for three months ended May 31, 2025, an improvement from prior year |
| Common Stock Shares | 10,000,000 | outstanding as of May 31, 2025, showing stability |
| Accumulated Deficit | $1,000 | as of May 31, 2025, indicating historical losses |
| Reporting Period End Date | 2024-11-30 | Indicates the end of the fiscal quarter for which financial information is reported. |
| Previous Fiscal Year End Date | 2023-08-31 | Provides a comparative point for financial performance. |
| Fiscal Year End | 2024 | The report covers the fiscal year ending August 31, 2024. |
Frequently Asked Questions
What are the latest SEC filings for Cnbx Pharmaceuticals Inc. (CNBX)?
Cnbx Pharmaceuticals Inc. has 12 recent SEC filings from Jan 2024 to Dec 2025, including 6 10-Q, 2 10-K, 2 8-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CNBX filings?
Across 12 filings, the sentiment breakdown is: 2 bearish, 10 neutral. The dominant sentiment is neutral.
Where can I find Cnbx Pharmaceuticals Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cnbx Pharmaceuticals Inc. (CNBX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cnbx Pharmaceuticals Inc.?
Key financial highlights from Cnbx Pharmaceuticals Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CNBX?
The investment thesis for CNBX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Cnbx Pharmaceuticals Inc.?
Key executives identified across Cnbx Pharmaceuticals Inc.'s filings include Dr. Erez Scapa, Dr. Dana Ben-Ami Shor, Dr. Gil Bar-Sela.
What are the main risk factors for Cnbx Pharmaceuticals Inc. stock?
Of CNBX's 10 assessed filings, 2 were flagged high-risk, 4 medium-risk, and 4 low-risk.
What are recent predictions and forward guidance from Cnbx Pharmaceuticals Inc.?
Forward guidance and predictions for Cnbx Pharmaceuticals Inc. are extracted from SEC filings as they are enriched.